Research Article
Oxidative Stress: Dual Pathway Induction in Cardiorenal Syndrome Type 1 Pathogenesis
Table 2
Medication of CRS Type 1 and AHF patients.
| | AHF | CRS Type 1 | value |
| Angiotensin-converting-enzyme inhibitor (ACEi) | 58% | 55% | NS | Angiotensin II receptor blockers (ARB) | 17% | 18% | NS | β-blocker | 66% | 63% | NS | Calcium antagonist | 25% | 27% | NS | Diuretics | 92% | 100% | NS | Statines | 50% | 55% | NS | Nonsteroidal anti-inflammatory drugs (NSAIDs) | 8% | 9% | NS |
|
|